Primary mesenchymal chondrosarcoma of the kidney is extremely rare, with only nine cases reported in the English literature. We report a new case of this disease. A 35-year-old man, presented with flank pain, episodic gross hematuria and a painless palpable mass in left abdominal quadrant. Computed tomography scan identified a left renal tumor with 20 cm, with no evidence of regional or metastatic spread disease. The patient underwent radical nephrectomy. The immunohistopathological diagnosis was mesenchymal chondrosarcoma of the kidney. At 18 months of follow-up, there was no evidence of recurrence or distant metastasis. Primary renal chondrosarcoma is so rare that its prognosis is unknown. Disease recurrence is unpredictable and when it is detected, the prognosis is poor. The radical nephrectomy with complete resection of the tumor with wide resection free margins is recommended, and the patients need long-term and close surveillance, with particular attention to local recurrence and uncommon sites of metastization.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/0973-1482.172121 | DOI Listing |
Int J Surg Case Rep
January 2025
Faculty of Medicine, University of Damascus, Damascus, Syrian Arab Republic.
Introduction: Mesenchymal chondrosarcoma (MC) is a high-grade variant of chondrosarcoma, essentially composed of poorly differentiated spindle cells interspersed with areas of cartilage or chondroid matrix. MC is extremely rare; it only accounts for 0.1 % of head and neck tumors and for only 1 % of all chondrosarcomas (CSs).
View Article and Find Full Text PDFDiscoveries (Craiova)
September 2024
Department of Oncopathology, Homi Bhabha Cancer Hospital (HBCH) and Mahamana Pandit Madan Mohan Malviya Cancer Centre (MPMMCC), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Varanasi, India.
Breast sarcomas are a diverse group of malignant neoplasms originating from the mammary stroma. They are uncommon tumors, often occurring as a component of other tumors. Among malignant breast mesenchymal tumors, pure sarcomas lacking epithelial components are even rarer, comprising only 0.
View Article and Find Full Text PDFJ Craniofac Surg
January 2025
Department of Pathology, Pathohistology and Medical Cytology, University Clinical Center of Serbia, Belgrade, Serbia.
Introduction: Sarcomas are relatively rare malignant tumors of mesenchymal origin, representing only about 1% of tumors in the head and neck region.
Materials And Methods: A retrospective study involved patients with sarcomas of the head and neck region who were diagnosed and treated over a 5-year period.
Results: Nine patients were included, 4 men and 5 women.
Biotechnol Bioeng
December 2024
Interdisciplinary Research Centre on Biomaterials (CRIB), University of Naples Federico II, Naples, Italy.
Chondrosarcomas (CHS) constitute approximately 20% of all primary malignant bone tumors, characterized by a slow growth rate with initial manifestation of few signs and symptoms. These malignant cartilaginous neoplasms, particularly those with dedifferentiated histological subtypes, pose significant therapeutic challenges, as they exhibit high resistance to both radiation and chemotherapy. Ranging from relatively benign, low-grade tumors (grade I) to aggressive high-grade tumors with the potential for lung metastases and a grim prognosis, there is a critical need for innovative diagnostic and therapeutic approaches, particularly for patients with more aggressive forms.
View Article and Find Full Text PDFJ Neurooncol
December 2024
Department of Neurosurgery, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands.
Purpose: Chordomas are malignant tumors of the axial spine and skull base, and they are notorious for their poor treatment response. Differentiating these tumors from comparatively less malignant chondrosarcomas is crucial for treatment and prognostication. Both tumor types differ in their developmental origin.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!